Ironshore Pharmaceuticals Announces PDUFA Date of August 8, 2018 for HLD200

09:27 EDT 12 Jul 2018 | Businesswire

This article has expired, however you can still download the PDF.
Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the ...

Other Sources for this Article

Ironshore Pharmaceuticals & Development, Inc.
Nelson F. Isabel, 647-260-7875
Chief Financial Officer


More From BioPortfolio on "Ironshore Pharmaceuticals Announces PDUFA Date of August 8, 2018 for HLD200"

Quick Search


Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...